Is cardiotoxicity a continuing risk after Herceptin treatment is finished?
• A: Cardiac monitoring should continue after completion of Herceptin treatment. • LVEF measurements every 6 months for at least 2 years following completion of Herceptin as a component of adjuvant therapy If Herceptin is withheld for significant cardiac dysfunction, LVEF measurement should be repeated at 4-week intervals. LVEF should be assessed by echocardiogram or MUGA scan.
